Literature DB >> 16323311

Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro.

A Dongari-Bagtzoglou1, C Cunha Villar, H Kashleva.   

Abstract

Oropharyngeal candidiasis (OPC) is the most common opportunistic infection in immunosuppressed patients. In OPC, Candida albicans persists intraepithelially triggering inflammatory events, without generally causing invasive infection. Since neutrophils play an important role in preventing invasive infection and since they establish contact with the microorganisms only within the epithelial cell layer, we examined the ability of Candida-infected oral epithelial cells to augment neutrophil-mediated hyphal damage in vitro. We found that challenge of neutrophils with hyphal organisms in the presence of C. albicans-infected oral epithelial cell supernatants resulted in a significantly greater suppression of hyphal cell metabolic activity compared to basal neutrophil anti-fungal function. Anti-hyphal activity in response to these supernatants was partly inhibited by neutralizing anti-IL-1alpha antibody and IL-1 receptor antagonist. Control supernatants from uninfected oral epithelial cells, as well as C. albicans conditioned-medium had a much less pronounced effect on neutrophil anti-fungal activity, which was not inhibited by these cytokine antagonists. We conclude that oral epithelial cells can act as activators of neutrophil anti-hyphal function, an effect that can be partly attributed to the generation of immunomodulatory cytokines during the interaction of oral mucosal cells with the pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16323311     DOI: 10.1080/13693780500064557

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  20 in total

Review 1.  Epithelial cells and innate antifungal defense.

Authors:  G Weindl; J Wagener; M Schaller
Journal:  J Dent Res       Date:  2010-04-15       Impact factor: 6.116

2.  [Morphology and diagnostics of superficial and invasive candidiasis. The pathologist's point of view].

Authors:  Elvira Stacher; Cord Langner
Journal:  Wien Med Wochenschr       Date:  2007

Review 3.  Oral innate immunity in HIV infection in HAART era.

Authors:  Wipawee Nittayananta; Renchuan Tao; Lanlan Jiang; Yuanyuan Peng; Yuxiao Huang
Journal:  J Oral Pathol Med       Date:  2015-01-31       Impact factor: 4.253

4.  Effects of bovine lactoferrin to oral Candida albicans and Candida glabrata isolates recovered from the saliva in elderly people.

Authors:  Akino Komatsu; Tazuko Satoh; Hiroyuki Wakabayashi; Fumiaki Ikeda
Journal:  Odontology       Date:  2015-01       Impact factor: 2.634

Review 5.  Th17 cells in immunity to Candida albicans.

Authors:  Nydiaris Hernández-Santos; Sarah L Gaffen
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 6.  Candida albicans interactions with epithelial cells and mucosal immunity.

Authors:  Julian R Naglik; David L Moyes; Betty Wächtler; Bernhard Hube
Journal:  Microbes Infect       Date:  2011-07-14       Impact factor: 2.700

Review 7.  Trained Innate Immunity and Its Implications for Mucosal Immunity and Inflammation.

Authors:  George Hajishengallis; Xiaofei Li; Ioannis Mitroulis; Triantafyllos Chavakis
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

8.  Host cell invasion and virulence mediated by Candida albicans Ssa1.

Authors:  Jianing N Sun; Norma V Solis; Quynh T Phan; Jashanjot S Bajwa; Helena Kashleva; Angela Thompson; Yaoping Liu; Anna Dongari-Bagtzoglou; Mira Edgerton; Scott G Filler
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 9.  Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis.

Authors:  Cristina Cunha Villar; Anna Dongari-Bagtzoglou
Journal:  Expert Rev Mol Med       Date:  2008-10-13       Impact factor: 5.600

10.  Epithelial GM-CSF induction by Candida glabrata.

Authors:  L Li; A Dongari-Bagtzoglou
Journal:  J Dent Res       Date:  2009-08       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.